A systematic review and meta-analysis on overall survival, failure-free survival and safety outcomes in patients with metastatic hormone-sensitive prostate cancer treated with new anti-androgens. | 2023 | Anti-Cancer Drugs |
Immune checkpoint inhibitor- and phosphatidylinositol-3-kinase inhibitor-related diabetes induced by antineoplastic drugs: two case reports and a literature review. | 2023 | Frontiers in Endocrinology |
Systemic therapies for high-volume metastatic hormone-sensitive prostate cancer: a network meta-analysis. | 2023 | Acta Oncologica |
Does Research from Clinical Trials in Metastatic Hormone-sensitive Prostate Cancer Treatment Translate into Access to Treatments for Patients in the "Real World"? A Systematic Review. | 2023 | European Urology Oncology |
The optimal upfront therapy in metastatic hormone-sensitive prostate cancer: A network meta-analysis. | 2023 | Journal of Cancer Research and Therapeutics |
Association of Second-generation Antiandrogens With Cognitive and Functional Toxic Effects in Randomized Clinical Trials: A Systematic Review and Meta-analysis. | 2023 | The optimal upfront therapy in metastatic hormone-sensitive prostate cancer: A network meta-analysis. |
Comparative efficacy of second-generation androgen receptor inhibitors for treating prostate cancer: A systematic review and network meta-analysis. | 2023 | Frontiers in Endocrinology |
First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer: A Living Systematic Review and Network Meta-analysis. | 2023 | JAMA Oncology |
The efficacy and adverse events of conventional and second-generation androgen receptor inhibitors for castration-resistant prostate cancer: A network meta-analysis | 2023 | Frontiers in Endocrinology |
Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. | 2023 | Prostate Cancer and Prostatic Diseases |
A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents. | 2022 | Anti-Cancer Drugs |
Androgen receptor signaling inhibitors in addition to docetaxel with androgen deprivation therapy for metastatic hormone- sensitive prostate cancer: a systematic review and meta-analysis. | 2022 | European Urology |
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. | 2021 | Prostate Cancer and Prostatic Diseases |
Comparison of systemic treatments for metastatic castration-sensitive prostate cancer: a systematic review and network meta-analysis. | 2021 | JAMA Oncology |
Seizures and neuropsychiatric toxicity in patients with non-metastatic crpc treated with new antiandrogens: systematic review and meta-analysis. | 2021 | Oncology Research and Treatment |
Overall survival after systemic treatment in high-volume versus low-volume metastatic hormone-sensitive prostate cancer: systematic review and network meta-analysis. | 2021 | European Urology Focus |
Neoadjuvant treatment with androgen receptor signaling inhibitors prior to radical prostatectomy: a systematic review. | 2021 | World Journal of Urology |
Comparison of treatments for nonmetastatic castration-resistant prostate cancer: matching-adjusted indirect comparison and network meta-analysis. | 2021 | Journal of the National Cancer Institute |
Apalutamide, darolutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer: a meta-analysis. | 2021 | Future Oncology |
Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer. | 2021 | NICE |
Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer. | 2021 | NICE |
Systemic therapies for metastatic hormone-sensitive prostate cancer: network meta-analysis. | 2021 | BJU International |
Risk of cardiovascular toxicities and hypertension in nonmetastatic castration-resistant prostate cancer patients treated with novel hormonal agents: a systematic review and meta-analysis. | 2021 | Expert Opinion on Drug Metabolism & Toxicology |
Comparative efficacy of apalutamide darolutamide and enzalutamide for treatment of non-metastatic castrate-resistant prostate cancer: a systematic review and network meta-analysis. | 2020 | Urologic Oncology |
Systemic management for nonmetastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. | 2020 | American Journal of Clinical Oncology |
A systematic review and network meta-analysis of novel androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer. | 2020 | Clinical Genitourinary Cancer |
Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. | 2020 | International Journal of Clinical Oncology |
First-line systemic therapy for metastatic castration-sensitive prostate cancer: an updated systematic review with novel findings. | 2020 | Critical Reviews in Oncology/Hematology |
Final clinical guidance report: apalutamide (Erleada) for metastatic castration-sensitive prostate cancer. | 2020 | CADTH |
Antiandrogen therapies for nonmetastatic castration-resistant prostate cancer: effectiveness and value. | 2018 | ICER |
Final clinical guidance report: apalutamide (Erleada) for castration-resistant prostate cancer. | 2018 | CADTH |
Management of non-metastatic castrate-resistant prostate cancer: a systematic review. | 2018 | Cancer Treatment Reviews |